Twice a year, influenza experts engage in a critically important forecasting bet: pick three to four vaccine strains now that will match the flu viruses people will face in 8-12 months. The strains ...

Invivyd, Inc. announced new in vitro data demonstrating that its investigational monoclonal antibody PEMGARDA™ (pemivibart) continues to show consistent neutralizing activity against the dominant SARS ...

Most notably, in vitro neutralization assays found significant increases in milk- and plasma-derived IgG neutralization efficacy, with estimated 60% and 90% improvements, respectively. Validating ...

A new study has shown that person-to-person variation in antibody immunity plays a key role in shaping which influenza (flu) strains dominate in a population. The work, published today as a Reviewed ...